BridgeBio Oncology Therapeutics Inc. (BBOT)
US — Healthcare Sector
Automate Your Wheel Strategy on BBOT
With Tiblio's Option Bot, you can configure your own wheel strategy including BBOT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBOT
- Rev/Share 0.0
- Book/Share 8.0497
- PB -34.5262
- Debt/Equity 0.0
- CurrentRatio 0.3335
- ROIC -0.0201
- MktCap 845820863.0
- FreeCF/Share -0.0489
- PFCF -735.325
- PE 53.2228
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0515
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BBOT | Leerink Partners | -- | Outperform | -- | $25 | Sept. 17, 2025 |
| Initiation | BBOT | H.C. Wainwright | -- | Buy | -- | $27 | Sept. 15, 2025 |
| Initiation | BBOT | Piper Sandler | -- | Overweight | -- | $21 | Aug. 15, 2025 |
News
About BridgeBio Oncology Therapeutics Inc. (BBOT)
- IPO Date 2025-08-12
- Website None
- Industry Biotechnology
- CEO Eli M. Wallace
- Employees 62
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.